Article
Clinical Manifestations, Mutational Analysis, and Immunological Phenotype in Patients with RAG1/2 Mutations: First Cases Series from Mexico and Description of Two Novel Mutations.
Journal of clinical immunology - 1 Aug 2021
Lugo-Reyes Saul Oswaldo, Pastor Nina, González-Serrano Edith, Yamazaki-Nakashimada Marco Antonio, Scheffler-Mendoza Selma, Berron-Ruiz Laura, Wakida Guillermo, Nuñez-Nuñez Maria Enriqueta, Macias-Robles Ana Paola, Staines-Boone Aide Tamara, Venegas-Montoya Edna, Alaez-Verson Carmen, Molina-Garay Carolina, Flores-Lagunes Luis Leonardo, Carrillo-Sanchez Karol, Niemela Julie, Rosenzweig Sergio D, Gaytan Paul, Yañez Jorge A, Martinez-Duncker Ivan, Notarangelo Luigi D, Espinosa-Padilla Sara, Cruz-Munoz Mario Ernesto
Abstract excerpt
Mutations in recombinase activating genes 1 and 2 (RAG1/2) result in human severe combined immunodeficiency (SCID). The products of these genes are essential for V(D)J rearrangement of the antigen receptors during lymphocyte development. Mutations resulting in null-recombination activity in RAG1 or RAG2 are associated with the most severe clinical and immunological phenotypes, whereas patients with hypomorphic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
